Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Expanded autologous ASCs · 1 trial · 2 indications
To evaluate safety and tolerability related to the intramuscular injection of autologous adipose derived stroma/ stem cells. \[ Designated as safety issue: Yes \]
| Arm | Type | Description |
|---|---|---|
| Autologous ASCs | OTHER | Expanded autologous ASCs (Adipose Stroma/Stem Cells) Intramuscular dose of 100 million expanded cells. |
| Name | Type | Description |
|---|---|---|
| Expanded autologous ASCs | BIOLOGICAL | Drug: Expanded autologous adipose-derived adult stroma/stem cells |
Inclusion Criteria: * Severe peripheral vascular disease not amenable to bypass or angioplasty * Age \>40 years old * Normal renal function (creatinine \< 1.6) * Non pregnant female * Lifespan \> 6 months Exclusion Criteria: * Age \<40 years old * Refusal to give informed consent and/orCognitivel...